Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients

MLA

Chen CC, et al. “Low-Density Lipoprotein Cholesterol Outcomes Post-Non-PCSK9i Lipid-Lowering Therapies in Atherosclerotic Cardiovascular Disease and Probable Heterozygous Familial Hypercholesterolemia Patients.” Therapeutics and Clinical Risk Management, vol. ume 14, Dec. 2018, pp. 2425–35. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.9e5fcf5fcd2147419f6864f44ac37dac&authtype=sso&custid=ns315887.

APA

Chen CC, Rane PB, Hines DM, Patel J, Harrison DJ, & Wade RL. (2018). Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients. Therapeutics and Clinical Risk Management, ume 14, 2425–2435.

Chicago

Chen CC, Rane PB, Hines DM, Patel J, Harrison DJ, and Wade RL. 2018. “Low-Density Lipoprotein Cholesterol Outcomes Post-Non-PCSK9i Lipid-Lowering Therapies in Atherosclerotic Cardiovascular Disease and Probable Heterozygous Familial Hypercholesterolemia Patients.” Therapeutics and Clinical Risk Management ume 14 (December): 2425–35. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.9e5fcf5fcd2147419f6864f44ac37dac&authtype=sso&custid=ns315887.